← Back to patent-cliff list
Berotralstat
Tier C — Watch / tradeBerotralstat
Biocryst Pharmaceuticals Inc
Originator
2020
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：KLKB1
Brand：ORLADEYO
Indications (approved)：遗传性血管性水肿
Regional status
US
Approved
2020-12-03
EU
Approved
2021-04-30
China
-
Japan
Approved
2021-01-22
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Berotralstat?
Approved indications include: 遗传性血管性水肿.
When does the Berotralstat patent expire?
No public expiry year is available for Berotralstat yet; this page updates once verified.
How do I get a quote for Berotralstat intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27